DLL3 and prostate cancer: Given our identification of putative GRNs in both murine and human treatment–resistant tumors, we explored the expression of several prostate cancer targets in our dataset, notably FOLH1 (PSMA), STEAP1/STEAP2, TACSTD2 (TROP2), CEACAM5 and DLL3, all of which have drug candidates in various stages of clinical development (1–5).